# Dan Marks

> Dan Marks is a Series A investor at RA Capital Management (Boston) backing Biotechnology. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management)
- Location: Boston, United States
- Total investments: 1
- Last investment: Apr 2022
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/dan-marks-03618290/

Dan Marks is a Series A investor at RA Capital Management in Boston focused on Biotechnology. Dan Marks is the Principal at RA Capital Management, L.P. Dan Marks attended Gerstner Sloan Kettering Graduate School of Biomedical Sciences at Memorial Sloan Kettering Cancer Center.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CDR-Life AG | CDR-Life is a Zurich-based biotech company that develops innovative therapeutic antibody fragments with a focus on immuno-oncology and ophthalmology. Our facilities are located in the Bio-Technopark in Schlieren-Zurich, Switzerland | $76M | Series A | Apr 13, 2022 |  |

1 of 1 investments shown.

## Co-investors
- [Jeito Capital](https://shizune.co/investors/profile/jeito-capital) — VC Fund, 1 deal together
- [Omega Funds](https://shizune.co/investors/profile/omega-funds) — VC Fund, 1 deal together

## About RA Capital Management

VC Fund · Boston, United States

RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.

5 contacts available at RA Capital Management.

| Name | Title | Profile |
| --- | --- | --- |
| Cristina Ghenoiu | Principal | https://shizune.co/investors/profile/cristina-ghenoiu |
| Ajay Yekkirala | VP, Head of Biology | https://shizune.co/investors/profile/ajay-yekkirala-9184 |
| Andrew Levin | Managing Director | https://shizune.co/investors/profile/andrew-levin |
| Barbara Herbst | Deputy Chief Compliance Officer | https://shizune.co/investors/profile/barbara-herbst |
| Dan Marks | Venture Senior Associate | https://shizune.co/investors/profile/dan-marks |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Dan Marks invest in?

Dan Marks invests primarily in Biotechnology startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Dan Marks last invest?

The most recent investment recorded for Dan Marks closed in Apr 2022. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co